Transmitted drug resistance (TDR) can impair the response to first-line antiretroviral therapy. In treatment-na€ ıve patients chronically infected with HIV type 1 (HIV-1), it was previously shown through Sanger sequencing that TDR was more common in men who have sex with men (MSM) than in other transmission risk groups. We aimed to compare two HIV-1 transmission groups in terms of the presence of TDR mutations.
Introduction
Transmitted drug resistance (TDR) can impair the response to first-line antiretroviral therapy. Indeed, the presence of TDR mutations can lead to a higher risk of virological failure if the affected drugs are introduced [1] . Surveillance of HIV type 1 (HIV-1) TDR is widely recommended, and it was shown that TDR was more common among men who have sex with men (MSM) and among patients infected with subtype B virus in the 2010/2011 French survey study conducted in antiretroviral-na€ ıve chronically HIV-1-infected patients using standard sequencing techniques [2] . Standard sequencing detects viral populations accounting for more than 15-20% of the viral population. However, HIV-1 minority resistant variants can be a source of virological failure: this has mainly been demonstrated for first-line regimens based on first-generation nonnucleoside reverse transcriptase inhibitors (NNRTIs) [3, 4] . The next-generation sequencing Correspondence: Dr Eve Todesco, Department of Virology, Bât CERVI, Hôpital Piti e-Salpêtri ere, 83 Bd de l'Hôpital, 75013 Paris, France. Tel: 33 1 42177426; fax: 33 1 42177411; e-mail: eve.todesco@aphp.fr technologies are able to detect these minority variants. Nevertheless, few data are available on the presence of minority TDR variants in treatment-na€ ıve patients in different HIV transmission risk groups [5] . The use of ultradeep sequencing (UDS) could allow detection of larger differences in TDR between transmission groups than Sanger sequencing can reveal. The aim of the study was to compare treatment-na€ ıve MSM and treatment-na€ ıve heterosexual patients chronically infected with HIV-1 in terms of the presence of TDR mutations, both in majority (> 20%) and in minority (1-20%) proportions.
Methods

Patients
Seventy treatment-na€ ıve heterosexual patients and 70 treatment-na€ ıve MSM recently diagnosed with HIV-1 infection were enrolled in the study. We performed Sanger sequencing [70 Reverse Transcriptase (RT) and 70 protease (PR) genes in each group] and UDS (70 RT and 70 PR sequences in the MSM group; 54 RT and 67 PR sequences in the heterosexual group). Patients were followed in the Department of Infectious Diseases of Piti e-Salpêtri ere and Bichat Claude Bernard hospitals (Paris, France). Information was obtained from the existing electronic database or medical records. Patients were informed that their demographic and clinical data would be recorded during their follow-up and could be used for retrospective studies and gave their consent. The study was approved by the Agence Nationale de Recherches sur le SIDA et les h epatites virales (ANRS) AC11 Ethics Committee.
Sanger sequencing
The first sample of plasma positive for HIV-1 was used for performing genotypic resistance testing. RT and PR genotypic analysis was conducted according to the ANRS consensus method [6] . PR and RT mutations were identified using the consensus statement of the list for TDR genotypic surveillance. [7] Additional analysis were performed with the International AIDS Society (IAS) list ( to have a mixture of wild-type and mutant amino acid residues at single positions were considered to have the mutation. The subtype determination was performed using the HIV Module of SMARTGENE (SmartGene, Zug, Switzerland), whose methodology is based on the Basic Local Alignment Search Tool (BLAST).
Ultradeep sequencing(UDS)
The steps involved in performing UDS up to pyrosequencing on GS Junior (Roche 454 â Life Sciences, Branford, CT) have been described previously [8] . . The primers used are available at http://www.hiv.frenchresistance.org. Pyrosequencing was performed according to the manufacturer's recommendations [9] . The GS Amplicon Variant Analyzer (Roche 454 â Life Sciences) was used to analyse the UDS results. Alignments were checked.
Statistical analysis
• To compare the baseline characteristics of the MSM and heterosexual populations, v 2 and MannÀWhitney tests were used for categorical (subtype) and continuous (age, viral load and CD4 cell count) variables, respectively.
• The global prevalences and the prevalences of TDR mutations by antiretroviral class were compared between the two groups using a v 2 test.
Results
An average of 5198 reads per nucleotide position were amplified, and the average error rates in controls (cellular clone 8E5) were 0.0012 and 0.0032 for RT and PR, respectively. These results allowed the accurate detection of variants down to 1% [10, 11] .
The characteristics of the patients were as follows: the median age was 36.3 years among the 70 MSM patients and 35.4 years among the 70 heterosexual patients (60% female), with no significant difference between the two populations. Sixty per cent of the patients were infected with HIV-1 subtype B in the MSM group, whereas 94% were infected with HIV-1 non-B subtypes in the heterosexual group. Among the MSM patients, the median viral load was 4.9 log 10 HIV-1 RNA copies/mL [interquartile range (IQR) 4.4-5.4 copies/mL] and the median CD4 cell count was 498 cells/lL (IQR 347-585 cells/lL). Among the heterosexual patients, the median viral load was 4.9 log 10 copies/mL (IQR 4.3-5.3 copies/mL) and the median CD4 cell count was 348 cells/lL (IQR 208-497 cells/lL). The HIV-1 viral loads were similar between the two groups, but the median CD4 cell count was higher among MSM than among heterosexual patients (P = 0.0016).
The global prevalence of TDR and prevalence by drug class are presented in Table 1 . A total concordance was found between Sanger sequencing and UDS for all majority mutations (>20%).
Sanger sequencing detected two nucleoside reverse transcriptase inhibitor (NRTI) TDR mutations in the viral genome of one MSM patient (M41L and T215C) and in the viral genome of three heterosexual patients (M41L and T215E, M184I, M184V, respectively); one NNRTI TDR mutation was detected in the viral genomes of two MSM patients (K103N) and one in the viral genomes of three heterosexual patients (K103N, Y181I and Y188L, respectively) and one protease inhibitor (PI) TDR mutation was detected in the viral genome of one heterosexual patient (I85V).
Within each group, we retrieved a higher prevalence of TDR mutations when UDS was performed: the prevalence of TDR was 18.6% [95% confidence interval (CI) 9.4À27.7%] with UDS vs. 4.3% (95% CI 0.0À9.1%) with Table 1 Global prevalence of transmitted drug resistance (TDR) and prevalence by drug class in the two groups: men who have sex with men (MSM) and heterosexual patients Heterosexual population (RT, n = 54; protease, n = 67) P-value Among the MSM, the prevalence of TDR detected using UDS was higher especially for NNRTIs and PIs (10.0% vs. 2.9% by Sanger sequencing and 7.1% vs. 0.0% by Sanger sequencing, respectively), while it was higher mainly for NRTIs and PIs among the heterosexual patients (14.8% vs. 4.3% by Sanger sequencing and 10.4% vs. 1.4% by Sanger sequencing, respectively).
The rate of TDR mutations only detected by UDS was low: between 1.1% and 4.8% for NRTIs, between 1.1% and 1.5% for NNRTIs and between 1.1% and 7.0% for PIs (Fig. 1) .
The global prevalence of TDR was not significantly different between the two groups, either by Sanger sequencing or by UDS. Nevertheless, a higher frequency of NRTI TDR was observed among heterosexual patients than among MSM (14.8% vs. 4.3%, respectively; P = 0.04).
We also found a trend for a higher frequency of TDR among MSM patients infected with HIV-1 subtype B compared with MSM patients infected with non-B HIV-1 subtypes [26.2% (n = 11/42) vs. 7.1% (n = 2/28) with UDS (P = 0.06); data not shown].
In addition, some resistance mutations, not considered in the list for TDR genotypic surveillance, but considered as major in some genotypic algorithms, were identified as minority variants. For instance, three K65E mutations were detected by UDS. With the latest version of the ANRS algorithm, the prevalence of resistance to the drugs recommended by the European AIDS Clinical Society (EACS) detected by UDS for NRTIs, NNRTIs and PIs was 2.9%, 12.8% and 7.1% among MSM patients and 11.1%, 5.6% and 11.9% among heterosexual patients, respectively.
Discussion
A higher prevalence of TDR was observed in antiretroviralna€ ıve chronically HIV-1-infected MSM and heterosexual populations when UDS was used compared with population sequencing. This suggests that powerful techniques such as UDS could improve the detection of HIV-1 TDR.
In the present study, UDS allowed us to detect a higher frequency of NRTI TDR in the heterosexual population than in MSM patients, although, on the basis of CD4 cell counts, the date of transmission seemed to be earlier in the heterosexual population. Usually, the more time goes by, the less TDR is detected. However, most thymidine analogue mutations were found to be highly stable without selection pressure. It was shown that NNRTI and PI mutations were, globally, less persistent than NRTI mutations, maybe because of a negative impact on viral fitness [11, 12] .
Otherwise, UDS showed a higher frequency of TDR in subtype B vs. subtype non-B viruses among MSM patients. This is consistent with previous findings obtained using Sanger sequencing in the Odyssee study in antiretroviral-na€ ıve chronically HIV-infected patients and in a study in French patients diagnosed at the time of primary HIV-1 infection [2, 13] .
The impact of minority TDR mutations on the response to treatment with first-generation NNRTIs is already well known [3, 4] , but further investigations for NRTI-, secondgeneration NNRTI-and PI-based regimens are obviously needed. Furthermore, the effects of minority TDR mutations on the response to integrase strand transfer inhibitors have not been studied in this work. As few data are available on this subject and are still controversial, more studies are needed [14, 15] . Nevertheless, an increase of TDR is predictable for this therapeutic class with the extensive use of these drugs and should be monitored in the future.
In conclusion, we found that UDS allowed sensitive monitoring of TDR, and was able to reveal some disparities in TDR between HIV transmission groups. The nextgeneration sequencing technology that we used probably detected minority resistant variants that were disappearing. The impact of these minority TDR mutations on the response to certain therapeutic classes and in particular the more recent drugs is unknown and should be further evaluated.
